Hyperbaric oxygen therapy for multiple sclerosis

CNS Neuroscience and Therapeutics

Volumn 16, Issue 2, 2010, Pages 115-124

  Bennett, Michael ^a   Heard, Robert ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hyperbaric oxygen; Meta analysis; Multiple sclerosis; Systematic review

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HYPERBARIC OXYGEN; META ANALYSIS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL DISORDER;

HUMANS; HYPERBARIC OXYGENATION; META-ANALYSIS AS TOPIC; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77749289863     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00129.x     Document Type: Review

References (61)

1. Compston D. The genetic epidemiology of multiple sclerosis. In : Compston D, Ebers GC, Lassmann H, McDonald WI, Matthews WB, Wekerle H, editors. McAlpine's Multiple Sclerosis, 3rd ed. London : Churchill Livingstone, 1998 45 142.
2. Flachenecker P, Stuke K. National MS registries. J Neurol 2008 255 (Suppl 6 102 108.
3. Weinschenker BG, Bass B, Rice GP. The natural history of multiple sclerosis: A geographically based study. Part 1. Clinical course and disability. Brain 1989 112 : 133 146. (Pubitemid 19056478)
4. Pittock SJ, Mayr WT, McClelland RL. Disability profile of MS didn't change over 10 years in a population-based prevalence cohort. Neurology 2004 62 : 601 606.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 58 : 840 846.
6. Ludwin SK. The pathogenesis of multiple sclerosis: Relating human pathology to experimental studies. J Neuropathol Exp Neurol 2006 65 : 305 318.
7. Gottlieb SF, Neubauer Ra. Multiple sclerosis: Its etiology, pathogenesis, and therapeutics with emphasis on the controversial use of HBO. J Hyperbaric Med 1988 3 : 143 164.
8. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. New England J Med 2006 354 : 942 955.
9. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nature Rev Neurosci 2002 3 : 291 301. (Pubitemid 135706608)
10. Chaudhuri A, Behan PO. Multiple sclerosis is not an autoimmune disease. Arch Neurol 2004 61 : 1610 1612.
11. Barnett MH, Prineas J. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004 55 : 458 468.
12. Scheinker M. Histogenesis of the early lesions of multiple sclerosis. Arch Neurol 1943 49 : 178 185.
13. Aita JF, Bennett DR, Anderson RE, Ziter F. Cranial CT appearance of acute multiple sclerosis. Neurology 1978 28 : 251 255.
14. Brickner RM. The significance of localized vasoconstrictions in multiple sclerosis. Transient sudden miniature attacks of multiple sclerosis. Assoc Respiratory, Nervous, and Mental Dis Proc 1950 29 : 236 244.
15. Rindfleisch E. Histologische detail zu der degeneration von gehirn und ruckenmark. Virchows Arch (Pathol Anat) 1863 26 : 478 483.
16. James PB. Evidence for subacute fat embolism as the cause of multiple sclerosis. Lancet 1982 1 : 380 386.
17. Dow RS, Berglund G. Vascular pattern of lesions of multiple sclerosis. Arch Neurol 1942 47 : 1 18.
18. Minagar A, Wenche J, Jiminez JJ, Alexander JS. Multiple sclerosis as a vascular disease. Neurol Res 2006 28 : 230 235.
19. Kirk J, Plumb J, Mirakhur M. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003 210 : 319 327.
20. Miller D, Khan OA, Sheremata WA. A controlled trial of natalizumab for relapsing multiple sclerosis. New England J Med 2003 348 : 15 23. (Pubitemid 36026342)
21. Chaudhuri A. Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ 2006 332 : 416 419.
22. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002 58 : 169 178.
23. Group PS. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352 : 1498 1504.
24. The Once Weekly Interferon for MSSG. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. Neurology 1999 53 : 679 686.
25. Patti F, L'Episcopo MR, Cataldi ML, Reggio A. Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study. Acta Neurol Scand 1999 100 : 283 289.
26. The European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 352 : 1491 1497.
27. Simon JH, Lull J, Jacobs LD, Rudick RA. A longitudinal study of T1 hypointense lesions in relapsing MS. MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000 55 : 185 192.
28. Group SS. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001 56 : 1496 1504.
29. Li DKB, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progresssive MS: MRI results. Neurology 2001 56 : 1505 1513.
30. Barbero P, Bergui M, Versino E, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb. Multiple Sclerosis 2006 12 : 72 76.
31. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: A rapid and systematic review. Health Technol Assess 2000 4 : 1 101.
32. Stangel M, Gold R, Gass A, Haas J, Jung S, Elias W, Zettl UK. Current issues in immunomodulatory treatment of multiple sclerosis. A practical appraoch. J Neurol 2006 253 : 32 36.
33. Waubant E, Goodkin K. Methodological problems in evaluating efficacy of a treatment for multiple sclerosis. Pathol Biol (Paris) 2000 48 : 104 113.
34. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing/remitting multiple sclerosis: Effects of heterogeeity of disease in placebo cohorts. J Neurol Neurosurg Psych 2000 68 : 450 457.
35. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983 33 : 1444 1452.
36. Kurtzke JF. Further notes on disability evaluation in multiple sclerosis with scale modifications. Neurology (Minneapolis) 1965 15 : 654 661.
37. Boschetty V, Dostal J, Holek J. Use of hyperbaric oxygenation in acute cerebrovascular accidents. (Preliminary report). Bratislavske lekarske listy 1970 53 : 160 164.
38. Neubauer RA. Treatment of multiple sclerosis with monoplace hyperbaric oxygenation. J Fla Med Assoc 1978 65 : 101.
39. Neubauer RA. Exposure of multiple sclerosis patients to hyperbaric oxygen at 1.5-2 ATA. A preliminary report. J Fla Med Assoc 1980 67 : 498 504.
40. Howick J (Updating: Phillips B, Ball C, Sackett D, Straus S, Haynes B, Dawes M, 1998). Oxford center for evidence-based medicine levels of evidence, 2009. Available from : http://www.cebm.net/?o=1025 Accessed 13 January 2010 MH, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004 : doi :.
41. Kleijnen J, Knipschild P. Hyperbaric oxygen for multiple sclerosis. Review of controlled trials. Acta Neurol Scand 1995 91 : 330 334.
42. Fischer BH, Marks M, Reich T. Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study. New England J Med 1983 308 : 181 186.
43. Neiman J, Nilsson BY, Barr PO, Perrins DJD. Hyperbaric oxygen in chronic progressive multiple sclerosis: Visual evoked potentials and clinical effects. J Neurol Neurosurg Psychiatry 1985 48 : 497 500.
44. Wood J, Stell R, Unsworth I, Lance JW, Skuse N. A double-blind trial of hyperbaric oxygen in the treatment of multiple sclerosis. Med J Aust 1985 143 : 238 241.
45. Slater GE, Anderson DA, Sherman R, Ettiger MG, Haglin J, Hitchcock C. Hyperbaric oxygen and multiple sclerosis: A double-blind, controlled study. Neurology 1985 35 : 315.
46. Erwin CW, Massey EW, Brendle AC, Shelton DL, Bennett PB. Hyperbaric oxygen influences on the visual evoked potentials in multiple sclerosis patients. Neurology 1985 35 : 104.
47. Massey EW, Shelton DL, Pact V, Greenburg J, Erwin W, Satzman H. Hyperbaric oxygen in multiple sclerosis: A double-blind crossover study of 18 patients. Neurology 1985 35 : 104.
48. Confavreux C, Mathieu C, Cacornac R, Aimard G, Devic M. Hyperbaric oxygen in multiple sclerosis. La Presse M, dicale 1986 15 : 1319 1322.
49. Wiles CM, Clarke CRA, Irwin HP, Edgar EF, Swan AV. Hyperbaric oxygen in multiple sclerosis: A double blind trial. BMJ (Clinical Research Edition) 1986 292 : 367 371.
50. Harpur GD, Suke R, Bass BH, et al. Hyperbaric oxygen therapy in chronic stable multiple sclerosis: Double-blind study. Neurology 1986 36 : 988 991.
51. Barnes MP, Bates D, Cartlidge NEF, French JM, Shaw DA. Hyperbaric oxygen and multiple sclerosis: Final results of a placebo-controlled, double-blind trial. J Neurol Neurosurg Psychiatry 1987 50 : 1402 1406.
52. Oriani G, Barbieri S, Cislaghi G, Albonico G, Scarlato G, Mariani C. Long-term hyperbaric oxygen in multiple sclerosis: A placebo-controlled, double-blind trial with evoked potentials studies. J Hyperbaric Med 1990 5 : 237 245.
53. L'Hermitte F, Roullet E, Lyon-Caen O, et al. Hyperbaric oxygen treatment of chronic multiple sclerosis. Results of a placebo-controlled double-blind study in 49 patients. Revue Neurologique (Paris) 1986 142 : 201 206.
54. Murthy KN, Maurice PB, Wilmeth JB. Double-blind randomised study of hyperbaric oxygen (HBO) versus placebo in multiple sclerosis (MS). Neurology 1985 35 : 104.
55. Worthington J, DeSouza L, Forti A, Jones R, Modarres-Sadeghi H, Blaney A. A double-blind controlled cross-over trial investigating the efficacy of hyperbaric oxygen in patients with multiple sclerosis. In : Rose FC, Jones R, editors. Multiple sclerosis, immunological, diagnostic and therapeutic aspects. Current problems in neurology 3. London : John Libbey, 1987 229 240.
56. Pallotta R. Hyperbaric therapy of multiple sclerosis. Minerva-Medica 1982 73 : 2947 2954.
57. Centers MSNT. The experience of MS National in treating MS with prolonged courses of high dosageoxygenation 2009.
58. Kindwall EP, McQuillen MP, Khatri BO, Grucho HW, Kindwall ML. Treatment of multiple sclerosis with hyperbaric oxygen. Results of a national registry. Arch Neurol 1991 48 : 195 199.
59. Neubauer RA. Hyperbaric oxygen therapy of multiple sclerosis. A multi-center survey. Lauderdale-By-The-Sea, Florida : RA Neubauer, 1983.
60. James PB. Hyperbaric oxygen and multiple sclerosis. Lancet 1985 1 : 572.
61. Gomez-Castillo JD, Bennett MH. The cost of hyperbaric therapy at the Prince of Wales Hospital, Sydney. South Pacific Underwater Med J 2005 35 : 194 198.